IBB241206P136000
- 0.16
- 0.000.00%
iShares Biotechnology ETF Newsroom
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday as Investors Anticipate Latest Inflation Data
This Owens Corning Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Mettler-Toledo Intl Analyst Ratings
IQVIA Hldgs Analyst Ratings
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
10 Health Care Stocks With Whale Alerts In Today's Session
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Demystifying Amgen: Insights From 13 Analyst Reviews
B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target
Biogen Analyst Ratings
B of A Securities Reinstates Underperform on Regeneron Pharmaceuticals, Announces $565 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Amgen Analyst Ratings
B of A Securities Reinstates Buy on Gilead Sciences, Announces $109 Price Target
Gilead Sciences Analyst Ratings
The USA healthcare system has long been in collapse! Industry executives: The CEO shooting incident has sounded the alarm for the industry.
① Mark Bertolini, CEO of Oscar Health, believes that the USA healthcare system is considered outdated and ineffective, which has led to a lack of sympathy from the public towards the assassination of Company Executives in the healthcare sector. ② The stock prices in the USA healthcare Industry have already been significantly affected by the shooting incident, and Analyst Jared Holz from Mizuho expects that subsequent uncertainties will continue.
Gilead Company Kite Reports Results From Five-year Follow-up Analysis Of ZUMA-5, A Phase 2 Study Of Yescarta
Regeneron Presents New And Updated Data For Odronextamab At ASH Annual Meeting